1. Scrip
  2. >>Business

Merck's Keytruda Claims Market Leadership In First-line Lung Cancer

 
• By Emily Hayes

Merck enjoyed a good second quarter, beating sales expectations for Keytruda and other drugs, which helped offset losses related to patent expirations.

3d illustration of T cells or cancer cells

Merck & Co. Inc.'s PD-1 inhibitor Keytruda performed well in the second quarter and has a dominant market position in first-line lung cancer with a 26% market share of new patient starts in the US – more than any other drug in that setting, the company reported July 28.

The company revealed above-consensus pharma sales of $8.8bn in the second quarter, up by 2% from the same period in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.